Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial

被引:296
|
作者
Hovorka, Roman [1 ,2 ]
Allen, Janet M. [1 ,2 ]
Elleri, Daniela [1 ,2 ]
Chassin, Ludovic J. [1 ,2 ]
Harris, Julie [2 ]
Xing, Dongyuan [3 ]
Kollman, Craig [3 ]
Hovorka, Tomas [1 ]
Larsen, Anne Mette F. [1 ,2 ]
Nodale, Marianna [1 ]
De Palma, Alessandro [1 ]
Wilinska, Malgorzata E. [1 ,2 ]
Acerini, Carlo L. [1 ,2 ]
Dunger, David B. [1 ,2 ]
机构
[1] Univ Cambridge, Dept Paediat, Cambridge CB2 0QQ, England
[2] Univ Cambridge, Inst Metab Sci, Cambridge CB2 0QQ, England
[3] Jaeb Ctr Hlth Res, Tampa, FL USA
来源
LANCET | 2010年 / 375卷 / 9716期
基金
英国医学研究理事会; 英国惠康基金;
关键词
SEVERE HYPOGLYCEMIA; GLUCOSE; ROADMAP;
D O I
10.1016/S0140-6736(09)61998-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Closed-loop systems link continuous glucose measurements to insulin delivery. We aimed to establish whether closed-loop insulin delivery could control overnight blood glucose in young people. Methods We undertook three randomised crossover studies in 19 patients aged 5-18 years with type 1 diabetes of duration 6.4 years (SD 4.0). We compared standard continuous subcutaneous insulin infusion and closed-loop delivery (n=13; APCam01); closed-loop delivery after rapidly and slowly absorbed meals (n=7; APCam02); and closed-loop delivery and standard treatment after exercise (n=10; APCam03). Allocation was by computer-generated random code. Participants were masked to plasma and sensor glucose. In APCam01, investigators were masked to plasma glucose. During closed-loop nights, glucose measurements were fed every 15 min into a control algorithm calculating rate of insulin infusion, and a nurse adjusted the insulin pump. During control nights, patients' standard pump settings were applied. Primary outcomes were time for which plasma glucose concentration was 3.91-8.00 mmol/L or 3.90 mmol/L or lower. Analysis was per protocol. This trial is registered, number ISRCTN18155883. Findings 17 patients were studied for 33 closed-loop and 21 continuous infusion nights. Primary outcomes did not differ significantly between treatment groups in APCam01 (12 analysed; target range, median 52% [IQR. 43-83] closed loop vs 39% [15-51] standard treatment, p=0.06; <= 3.90 mmol/L, 1% [0-7] vs 2% [0-41], p=0.13), APCam02 (six analysed; target range, rapidly 53% [48-57] vs slowly absorbed meal 55% [37-64], p=0.97; <= 3.90 mmol/L, 0% [0-4] vs 0% [0-0], p=0.16]), and APCam03 (nine analysed; target range 78% [60-92] closed loop vs 43% [25-65] control, p=0.0245, not significant at corrected level; <= 3.90 mmol/L, 10% [2-15] vs 6% [0-44], p=0.27). A secondary analysis of pooled data documented increased time in the target range (60% [51-88] vs 40% [18-61]; p=0.0022) and reduced time for which glucose concentrations were 3.90 mmol/L or lower (2.1% (0.0-10.0) vs 4.1% (0.0-42.0); p=0.0304). No events with plasma glucose concentration lower than 3.0 mmol/L were recorded during closed-loop delivery compared with nine events during standard treatment. Interpretation Closed-loop systems could reduce risk of nocturnal hypoglycaemia in children and adolescents with type 1 diabetes.
引用
收藏
页码:743 / 751
页数:9
相关论文
共 50 条
  • [1] Closed-loop insulin delivery systems in children and adolescents with type 1 diabetes
    Dovc, Klemen
    Battelino, Tadej
    EXPERT OPINION ON DRUG DELIVERY, 2020, 17 (02) : 157 - 166
  • [2] HOME USE OF DAY-AND-NIGHT CLOSED-LOOP INSULIN DELIVERY IN ADOLESCENTS WITH TYPE 1 DIABETES: A RANDOMISED CLINICAL TRIAL
    Tauschmann, M.
    Allen, J. A.
    Wilinska, M. E.
    Thabit, H.
    Acerini, C. L.
    Dunger, D. B.
    Hovorka, R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A21 - A22
  • [3] Closed-Loop Insulin Delivery in Type 1 Diabetes
    Thabit, Hood
    Hovorka, Roman
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2012, 41 (01) : 105 - +
  • [4] Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial
    Thabit, Hood
    Hartnell, Sara
    Allen, Janet M.
    Lake, Andrea
    Wilinska, Malgorzata E.
    Ruan, Yue
    Evans, Mark L.
    Coll, Anthony P.
    Hovorka, Roman
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (02): : 117 - 124
  • [5] A Randomized Trial of Closed-Loop Insulin Delivery Postpartum in Type 1 Diabetes
    Donovan, Lois E.
    Feig, Denice S.
    Lemieux, Patricia
    Murphy, Helen R.
    Bell, Rhonda C.
    Sigal, Ronald J.
    Ho, Josephine
    Virtanen, Heidi
    Crawford, Susan
    Yamamoto, Jennifer M.
    DIABETES CARE, 2023, 46 (12) : 2258 - 2266
  • [6] Enlarging the loop: closed-loop insulin delivery for type 1 diabetes
    Galderisi, Alfonso
    Sherr, Jennifer L.
    LANCET, 2018, 392 (10155): : 1282 - 1284
  • [7] Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial
    Ahmad Haidar
    Leif Erik Lovblom
    Nancy Cardinez
    Nikita Gouchie-Provencher
    Andrej Orszag
    Michael A. Tsoukas
    C. Marcelo Falappa
    Adnan Jafar
    Milad Ghanbari
    Devrim Eldelekli
    Joanna Rutkowski
    Jean-François Yale
    Bruce A. Perkins
    Nature Medicine, 2022, 28 : 1269 - 1276
  • [8] Closed-loop insulin delivery for treatment of type 1 diabetes
    Daniela Elleri
    David B Dunger
    Roman Hovorka
    BMC Medicine, 9
  • [9] Closed-loop insulin delivery for treatment of type 1 diabetes
    Elleri, Daniela
    Dunger, David B.
    Hovorka, Roman
    BMC MEDICINE, 2011, 9
  • [10] Closed-Loop Insulin Delivery Postpartum in Type 1 Diabetes
    Donovan, Lois E.
    Feig, Denice
    Lemieux, Patricia
    Murphy, Helen R.
    Bell, Rhonda C.
    Sigal, Ronald J.
    Ho, Josephine
    Yamamoto, Jennifer M.
    DIABETES, 2023, 72